GlobeNewswire Inc.··NaDuvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease
Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease